Skip to main content




Autoimmune diseases

We understand how distressing and debilitating immune-mediated inflammatory diseases (IMIDs) can be, which is why we strive to provide treatments that give you or your loved ones relief from the daily discomfort and stress that these conditions can pose. We are committed to building on our breakthroughs that have already changed the lives of millions of people around the world.

Our Commitment to Patients

Janssen is committed to helping ease the storm that people living with immune-mediated inflammatory diseases have to endure for the rest of their lives.

Our goal at Janssen is to improve the diagnosis of immune-mediated inflammatory diseases, improve patients’ access to the most appropriate treatments and continue to develop new medicines that address unmet medical needs.

We never underestimate the human impact of immune-mediated inflammatory diseases.

People living with immune-mediated inflammatory diseases can face a lifetime of managing their condition, yet the impact of these diseases is sometimes underestimated. As some of these diseases are not readily recognised, people may suffer silently before eventually receiving treatment.

Immune-mediated inflammatory diseases are the result of a relentless, internal, immunological ‘storm’, which can cause pain and discomfort that many people live with every day.1,2,3 People may experience stigma, isolation, decreased productivity and psychological issues.2,4,5,6,7 And it’s not just them, their families and loved ones can be affected too.

Our mission is clear: We won't rest until we achieve a world free from immune-mediated inflammatory diseases.

Our work in ImmunologyOur Disease Areas of Focus

We focus on a range of the most common immune-mediated inflammatory diseases, where the impact on patients is highest and where there remains an unmet need for treatment.


Our focus in Dermatology is inflammatory conditions of the skin.

Psoriasis is a condition which causes symptoms on the skin and sometimes the joints. When a person has psoriasis, their skin replacement process speeds up and the resulting accumulation of skin cells forms raised ‘plaques’ on the skin which can be flaky, scaly, discoloured, and itchy.8 Psoriasis can occur on any area of the body, including the elbows, knees or scalp, though it can appear on any location although different types tend to occur on different areas.8


Our focus in Rheumatology is currently inflammatory disorders of the joints and skin.

Psoriatic arthritis is a type of inflammatory arthritis which affects joints (such as the knees) as well as areas where tendons join to bone (such as the heel and lower back). Most people who have psoriatic arthritis find it occurs after developing skin psoriasis, but some develop the arthritis before they notice any psoriasis on their skin.9


Our focus in Gastroenterology is inflammatory bowel disease.

Autoimmune diseases

Crohn’s disease and ulcerative colitis are forms of inflammatory bowel disease (IBD). They cause inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhoea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract, whereas ulcerative colitis is limited to the colon.10

Other auto-immediated conditions

Lupus is a long-term condition that causes joint pain, skin rashes and tiredness. It is currently incurable, but symptoms can be managed through treatment. The two major symptoms are joint and muscle pain and an extreme tiredness that won't go away no matter how much you rest. Whilst the two major symptoms are invariably present, people with lupus can experience a wide range of symptoms including inflammation of different parts of the body including the lungs, heart, liver, joints and kidneys.11

Working together to achieve a world where immune-mediated inflammatory diseases are a thing of the past.

Explore More


Janssen in the UK







1. Lofvendahl, S., et al. Incremental costs for psoriasis and psoriatic arthritis in a population-based cohort in southern Sweden: is it all psoriasis-attributable morbidity? Journal of Rheumatology, 2016;43(3):640-647
2. Lonffors, S., et al. IBD and health-related quality of life - discovering the true impact. Journal of Crohn's and Colitis, 2014;8:1281-1286
3. Najafi, S., et al. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. Clin Rheumatol, 2020;39:3223–3235
4. Eghlileb, A.M., et al. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol, 2007;156(6):1245-50
5. Dibley, L., et al. The experience of stigma in inflammatory bowel disease: An interpretive (hermeneutic) phenomenological study. J Adv Nurs, 2018;74:838-851
6. Ograczyk, A., et al. Itch, disease coping strategies and quality of life in psoriasis patients. Postepy Dermatologi Alergologii, 2014;5:299-304
7. Narayanan, S., et al. 2014. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study. Psoriasis (Auckl), 2014;5:1-7
8. National Psoriasis foundation. About Psoriasis. Available at: Last accessed May 2022.
9. NHS UK. Psoriatic arthritis. Available at: Last accessed May 2022.
10. Crohn’s and Colitis UK. Understanding Crohn’s and colitis. Available at: Last accessed May 2022.
11. NHS UK. Lupus. Available at: Last accessed May 2022.
12. Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116

CP-322382 | June 2022